A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Our products include a variety of primary proprietary packaging, containment solutions, reconstitution and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services and integrated solutions. Our customers include leading biologic, generic, pharmaceutical, diagnostic, and medical device companies in the world. Our top priority is delivering quality products that meet the exact product specifications and quality standards customers require and expect. This focus on quality includes a commitment to excellence in manufacturing, scientific and technical expertise and management, which enables us to partner with our customers in order to deliver safe, effective drug products to patients quickly and efficiently.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 3.1B | 3.1B | 2.9B | 2.9B | 2.9B | 2.8B |
| Net Income | 494M | 494M | 493M | 593M | 586M | 662M |
| EPS | $6.79 | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 |
| Free Cash Flow | 469M | 469M | 276M | 415M | 439M | 331M |
| ROIC | 17.3% | 24.4% | 23.1% | 37.6% | 50.3% | 56.8% |
| Gross Margin | 35.9% | 35.9% | 34.5% | 38.3% | 39.4% | 41.5% |
| Debt/Equity | 0.10 | 0.10 | 0.11 | 0.11 | 0.12 | 0.14 |
| Dividends/Share | $0.84 | $0.86 | $0.82 | $0.78 | $0.74 | $0.70 |
| Operating Income | 585M | 585M | 570M | 676M | 734M | 752M |
| Operating Margin | 19.0% | 19.0% | 19.7% | 22.9% | 25.4% | 26.6% |
| ROE | 15.5% | 16.9% | 18.4% | 20.6% | 21.8% | 28.3% |
| Shares Outstanding | 73M | 73M | 74M | 75M | 76M | 76M |
WEST PHARMACEUTICAL SERVICES INC passes 7 of 9 quality checks, indicating strong fundamentals.
WEST PHARMACEUTICAL SERVICES INC trades at 38.3x trailing earnings, compared to its 15-year median P/E of 45.5x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 39.9x vs a median of 50.7x. The company's 5-year average ROIC is 38.4% with a gross margin of 37.9%. Total shareholder yield (dividends + buybacks) is 1.0%. At current prices, the estimated annualized return to fair value is +11.3%.
WEST PHARMACEUTICAL SERVICES INC (WST) has a current P/E ratio of 38.3, compared to its historical median P/E of 45.5. The stock is currently considered Fair based on its historical valuation range.
WEST PHARMACEUTICAL SERVICES INC (WST) has a 5-year average return on invested capital (ROIC) of 38.4%. This indicates strong capital allocation and a potential competitive advantage.
WEST PHARMACEUTICAL SERVICES INC (WST) has a market capitalization of $18.9B. It is classified as a large-cap stock.
Yes, WEST PHARMACEUTICAL SERVICES INC (WST) pays a dividend with a trailing twelve-month yield of 0.32%. The company also returns capital through share buybacks, with a buyback yield of 0.71%.
Based on historical P/E analysis, WEST PHARMACEUTICAL SERVICES INC (WST) appears fair. The current P/E of 38.3 is 16% below its historical median of 45.5. The estimated fair value CAGR (P/E method) is 16.1%.
WEST PHARMACEUTICAL SERVICES INC (WST) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
WEST PHARMACEUTICAL SERVICES INC (WST) reported annual revenue of $3.1 billion in its most recent fiscal year, based on SEC EDGAR filings.
WEST PHARMACEUTICAL SERVICES INC (WST) has a net profit margin of 16.1%. This is a healthy margin.
WEST PHARMACEUTICAL SERVICES INC (WST) generated $469 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
WEST PHARMACEUTICAL SERVICES INC (WST) has a debt-to-equity ratio of 0.10. This indicates a conservatively financed balance sheet.
WEST PHARMACEUTICAL SERVICES INC (WST) reported earnings per share (EPS) of $6.79 in its most recent fiscal year.
WEST PHARMACEUTICAL SERVICES INC (WST) has a return on equity (ROE) of 16.9%. This indicates the company generates strong returns for shareholders.
WEST PHARMACEUTICAL SERVICES INC (WST) has a 5-year average gross margin of 37.9%. This indicates decent pricing power.
The Ledger Terminal provides 18 years of financial data for WEST PHARMACEUTICAL SERVICES INC (WST), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
WEST PHARMACEUTICAL SERVICES INC (WST) has a book value per share of $43.68, based on its most recent annual SEC filing.